Coherus Oncology (CHRS) Exchange Rate Effect (2014 - 2019)
Coherus Oncology (CHRS) posted Exchange Rate Effect of -$106000.0 for Q4 2019, down 279.66% sequentially from $59000.0 in Q3 2019, and down 176.81% YoY from $138000.0 in Q4 2018.
Coherus Oncology (CHRS) Exchange Rate Effect (2014 - 2019) Analysis & Trends
Coherus Oncology has reported Exchange Rate Effect for 6 years, with the latest figure at -$106000.0 in Q4 2019.
- Quarterly Exchange Rate Effect fell 176.81% year-over-year to -$106000.0 in Q4 2019, while the trailing twelve-month figure through Mar 2020 was -$140000.0 (down 140.58% YoY) and the FY2019 annual result came in at -$276000.0, down 158.97% from the prior year.
- Exchange Rate Effect fell to -$106000.0 in Q4 2019 per CHRS's latest filing, from $59000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $226000.0 in Q2 2018 and troughed at -$271000.0 in Q4 2016.
- A 5-year average of -$12100.0 and a median of -$28000.0 in 2015 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2018 and 2019: Exchange Rate Effect soared 2071.43% in 2018, then sank 946.15% in 2019.
- Over 5 years, Exchange Rate Effect stood at $82000.0 in 2015, then plunged by 430.49% to -$271000.0 in 2016, then jumped by 97.42% to -$7000.0 in 2017, then jumped by 2071.43% to $138000.0 in 2018, then plunged by 176.81% to -$106000.0 in 2019.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$106000.0, $59000.0, and -$93000.0 for Q4 2019, Q3 2019, and Q2 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -106,000.00 |
| Dec 31, 2019 | -106,000.00 |
| Sep 30, 2019 | 59,000.00 |
| Sep 30, 2019 | 59,000.00 |
| Jun 30, 2019 | -93,000.00 |
| Jun 30, 2019 | -93,000.00 |
| Mar 31, 2019 | -136,000.00 |
| Mar 31, 2019 | -136,000.00 |
| Dec 31, 2018 | 138,000.00 |
| Dec 31, 2018 | 138,000.00 |
| Sep 30, 2018 | 117,000.00 |
| Sep 30, 2018 | 117,000.00 |
| Jun 30, 2018 | 226,000.00 |
| Jun 30, 2018 | 226,000.00 |
| Mar 31, 2018 | -13,000.00 |
| Mar 31, 2018 | -13,000.00 |
| Dec 31, 2017 | -7,000.00 |
| Dec 31, 2017 | -7,000.00 |
| Sep 30, 2017 | -70,000.00 |
| Sep 30, 2017 | -70,000.00 |